SG11201702874YA - Triazolopyrazinones as pde1 inhibitors - Google Patents
Triazolopyrazinones as pde1 inhibitorsInfo
- Publication number
- SG11201702874YA SG11201702874YA SG11201702874YA SG11201702874YA SG11201702874YA SG 11201702874Y A SG11201702874Y A SG 11201702874YA SG 11201702874Y A SG11201702874Y A SG 11201702874YA SG 11201702874Y A SG11201702874Y A SG 11201702874YA SG 11201702874Y A SG11201702874Y A SG 11201702874YA
- Authority
- SG
- Singapore
- Prior art keywords
- triazolopyrazinones
- pde1 inhibitors
- pde1
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201400582 | 2014-10-10 | ||
| PCT/EP2015/073417 WO2016055618A1 (en) | 2014-10-10 | 2015-10-09 | Triazolopyrazinones as pde1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201702874YA true SG11201702874YA (en) | 2017-05-30 |
Family
ID=58698606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201702874YA SG11201702874YA (en) | 2014-10-10 | 2015-10-09 | Triazolopyrazinones as pde1 inhibitors |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US10150771B2 (en) |
| EP (1) | EP3204387B1 (en) |
| JP (1) | JP6596489B2 (en) |
| KR (1) | KR20170066417A (en) |
| CN (1) | CN106715438B (en) |
| AR (1) | AR102227A1 (en) |
| AU (1) | AU2015329898A1 (en) |
| BR (1) | BR112017006940A2 (en) |
| CA (1) | CA2961986A1 (en) |
| CL (1) | CL2017000817A1 (en) |
| CO (1) | CO2017002708A2 (en) |
| DO (1) | DOP2017000080A (en) |
| EA (1) | EA201790575A1 (en) |
| EC (1) | ECSP17018120A (en) |
| ES (1) | ES2735733T3 (en) |
| IL (1) | IL251420A0 (en) |
| MX (1) | MX2017004510A (en) |
| PE (1) | PE20180024A1 (en) |
| PH (1) | PH12017500621A1 (en) |
| RU (1) | RU2017111888A (en) |
| SG (1) | SG11201702874YA (en) |
| SV (1) | SV2017005419A (en) |
| TN (1) | TN2017000099A1 (en) |
| TW (1) | TW201629064A (en) |
| WO (1) | WO2016055618A1 (en) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201629064A (en) | 2014-10-10 | 2016-08-16 | Ｈ 朗德貝克公司 | Triazolopyrainones as PDE1 inhibitors |
| TW201643167A (en) * | 2015-04-22 | 2016-12-16 | Ｈ 朗德貝克公司 | Imidazotriazinones as PDE1 inhibitors |
| JO3627B1 (en) | 2015-04-30 | 2020-08-27 | H Lundbeck As | Imidazopyrazinones as PDE1 inhibitors |
| TWI729109B (en) | 2016-04-12 | 2021-06-01 | 丹麥商Ｈ 朗德貝克公司 | 1,5-DIHYDRO-4H-PYRAZOLO[3,4-d]PYRIMIDIN-4-ONES AND 1,5-DIHYDRO-4H-PYRAZOLO[4,3-c]PYRIDIN-4-ONES AS PDE1 INHIBITORS |
| US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| JOP20170164A1 (en) * | 2016-08-25 | 2019-01-30 | Lilly Co Eli | Triazolopyrazinone derivative useful as a human pde1 inhibitor |
| WO2018073251A1 (en) | 2016-10-18 | 2018-04-26 | H. Lundbeck A/S | Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as pde1 inhibitors |
| CN109803653A (en) | 2016-10-28 | 2019-05-24 | H.隆德贝克有限公司 | Combined therapy including giving Imidazopyrazines ketone |
| MX2019004763A (en) | 2016-10-28 | 2019-07-01 | H Lundbeck As | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders. |
| JOP20190126A1 (en) | 2016-12-22 | 2019-05-28 | H Lundbeck As | Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors |
| EP3562828A1 (en) | 2016-12-28 | 2019-11-06 | Dart NeuroScience LLC | Substituted pyrazolopyrimidinone compounds as pde2 inhibitors |
| AR112457A1 (en) * | 2017-08-02 | 2019-10-30 | Lilly Co Eli | DERIVATIVES OF [1,2,4] TRIAZOLO [4,3-A] PIRAZIN-6 (5H) -ONE |
| US11434247B1 (en) | 2017-11-27 | 2022-09-06 | Dart Neuroscience Llc | Substituted furanopyrimidine compounds as PDE1 inhibitors |
| SG11202005361RA (en) | 2017-12-14 | 2020-07-29 | H Lundbeck As | Combination treatments comprising administration of 1h-pyrazolo[4,3-b]pyridines |
| AR113926A1 (en) * | 2017-12-14 | 2020-07-01 | H Lundbeck As | DERIVATIVES OF 1H-PYRAZOLE [4,3-B] PYRIDINES |
| US10766893B2 (en) * | 2017-12-20 | 2020-09-08 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| TW201927784A (en) * | 2017-12-20 | 2019-07-16 | 丹麥商Ｈ 朗德貝克公司 | Macrocycles as PDE1 inhibitors |
| JP7194738B2 (en) | 2017-12-20 | 2022-12-22 | ハー・ルンドベック・アクチエゼルスカベット | Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as PDE1 inhibitors |
| US11453673B2 (en) * | 2018-02-06 | 2022-09-27 | Eli Lilly And Company | Substituted [1,2,4]triazolo[4,3-a]pyrazines as phosphodiesterase inhibitors |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB973361A (en) | 1960-05-11 | 1964-10-28 | Ciba Ltd | Pyrazolo-pyrimidines and process for their manufacture |
| DE10238722A1 (en) | 2002-08-23 | 2004-03-11 | Bayer Ag | Improving attention, concentration, cognition, learning and/or memory performance, using selective phosphodiesterase 9A inhibitors, preferably 4H-pyrazolo-(3,4-d)-pyrimidin-4-one derivatives |
| DE10238723A1 (en) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl substituted pyrazolyprimidines |
| DE10238724A1 (en) | 2002-08-23 | 2004-03-04 | Bayer Ag | New 6-alkyl-1,5-dihydro-4H-pyrazolo-(3,4-d)-pyrimidin-4-ones useful as selective phosphodiesterase 9A inhibitors for improving attention, concentration, learning and/or memory performance |
| WO2004099211A1 (en) | 2003-05-09 | 2004-11-18 | Bayer Healthcare Ag | 6-cyclylmethyl- and 6-alkylmethyl-substituted pyrazolopyrimidines |
| WO2006068978A2 (en) | 2004-12-21 | 2006-06-29 | Takeda Pharmaceutial Company Limited | Dipeptidyl peptidase inhibitors |
| EP1919287A4 (en) | 2005-08-23 | 2010-04-28 | Intra Cellular Therapies Inc | Organic compounds for treating reduced dopamine receptor signalling activity |
| US9006258B2 (en) | 2006-12-05 | 2015-04-14 | Intra-Cellular Therapies, Inc. | Method of treating female sexual dysfunction with a PDE1 inhibitor |
| ATE540954T1 (en) | 2007-05-11 | 2012-01-15 | Pfizer | AMINOHETEROCYCLIC COMPOUNDS |
| UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
| EA201100446A1 (en) | 2008-09-08 | 2011-10-31 | Бёрингер Ингельхайм Интернациональ Гмбх | PYRAZOLOPYRIMIDINES AND THEIR APPLICATION FOR THE TREATMENT OF CNS DAMAGE |
| GEP20146046B (en) | 2008-12-06 | 2014-02-25 | Intracellular Therapies Inc | Organic compounds |
| TWI404721B (en) | 2009-01-26 | 2013-08-11 | Pfizer | Amino-heterocyclic compounds |
| JP5879336B2 (en) * | 2010-05-31 | 2016-03-08 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | Organic compounds |
| AR083058A1 (en) | 2010-09-20 | 2013-01-30 | Envivo Pharmaceuticals Inc | IMIDAZOTRIAZINONA STRUCTURE COMPOUNDS |
| EP2619204A4 (en) * | 2010-09-21 | 2014-08-27 | Merck Sharp & Dohme | Triazolopyrazinones as p2x7 receptor antagonists |
| JP6051210B2 (en) | 2011-06-10 | 2016-12-27 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | Organic compounds |
| CA2886885C (en) | 2011-10-10 | 2019-07-16 | H. Lundbeck A/S | Pde9i with imidazo pyrazinone backbone |
| EP2807163B1 (en) | 2012-01-26 | 2017-03-22 | H. Lundbeck A/S | Pde9 inhibitors with imidazo triazinone backbone |
| WO2013192229A1 (en) | 2012-06-18 | 2013-12-27 | Dart Neuroscience (Cayman) Ltd | Substituted pyridine azolopyrimidine - 5 - (6h) - one compounds |
| AU2014234990B2 (en) | 2013-03-15 | 2017-11-16 | Intra-Cellular Therapies, Inc. | Organic compounds |
| JP5783297B2 (en) | 2013-08-06 | 2015-09-24 | 株式会社デンソー | Mechanical quantity sensor |
| JP5797815B1 (en) | 2014-06-27 | 2015-10-21 | 細田建設株式会社 | Post-installed anchor and its construction method |
| WO2016042775A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic derivative |
| US20160083391A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic piperazine derivative |
| US20160083400A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic guanidine derivative |
| TW201629064A (en) | 2014-10-10 | 2016-08-16 | Ｈ 朗德貝克公司 | Triazolopyrainones as PDE1 inhibitors |
| WO2016147659A1 (en) | 2015-03-16 | 2016-09-22 | Sumitomo Dainippon Pharma Co., Ltd. | Bicyclic imidazolo derivative |
| TW201643167A (en) | 2015-04-22 | 2016-12-16 | Ｈ 朗德貝克公司 | Imidazotriazinones as PDE1 inhibitors |
| JO3627B1 (en) | 2015-04-30 | 2020-08-27 | H Lundbeck As | Imidazopyrazinones as PDE1 inhibitors |
| AR107456A1 (en) | 2016-02-12 | 2018-05-02 | Lilly Co Eli | PDE1 INHIBITOR |
| TWI729109B (en) | 2016-04-12 | 2021-06-01 | 丹麥商Ｈ 朗德貝克公司 | 1,5-DIHYDRO-4H-PYRAZOLO[3,4-d]PYRIMIDIN-4-ONES AND 1,5-DIHYDRO-4H-PYRAZOLO[4,3-c]PYRIDIN-4-ONES AS PDE1 INHIBITORS |
| WO2018073251A1 (en) | 2016-10-18 | 2018-04-26 | H. Lundbeck A/S | Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as pde1 inhibitors |
| MX2019004763A (en) | 2016-10-28 | 2019-07-01 | H Lundbeck As | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders. |
| CN109803653A (en) | 2016-10-28 | 2019-05-24 | H.隆德贝克有限公司 | Combined therapy including giving Imidazopyrazines ketone |
-
2015
- 2015-10-08 TW TW104133183A patent/TW201629064A/en unknown
- 2015-10-09 WO PCT/EP2015/073417 patent/WO2016055618A1/en active Application Filing
- 2015-10-09 US US15/517,348 patent/US10150771B2/en active Active
- 2015-10-09 AU AU2015329898A patent/AU2015329898A1/en not_active Abandoned
- 2015-10-09 EA EA201790575A patent/EA201790575A1/en unknown
- 2015-10-09 AR ARP150103269A patent/AR102227A1/en unknown
- 2015-10-09 JP JP2017518482A patent/JP6596489B2/en active Active
- 2015-10-09 MX MX2017004510A patent/MX2017004510A/en unknown
- 2015-10-09 ES ES15787486T patent/ES2735733T3/en active Active
- 2015-10-09 CN CN201580052980.2A patent/CN106715438B/en active Active
- 2015-10-09 RU RU2017111888A patent/RU2017111888A/en unknown
- 2015-10-09 KR KR1020177009566A patent/KR20170066417A/en unknown
- 2015-10-09 EP EP15787486.8A patent/EP3204387B1/en active Active
- 2015-10-09 PE PE2017000481A patent/PE20180024A1/en not_active Application Discontinuation
- 2015-10-09 CA CA2961986A patent/CA2961986A1/en not_active Abandoned
- 2015-10-09 SG SG11201702874YA patent/SG11201702874YA/en unknown
- 2015-10-09 BR BR112017006940A patent/BR112017006940A2/en not_active Application Discontinuation
- 2015-10-09 TN TN2017000099A patent/TN2017000099A1/en unknown
-
2017
- 2017-03-21 DO DO2017000080A patent/DOP2017000080A/en unknown
- 2017-03-22 CO CONC2017/0002708A patent/CO2017002708A2/en unknown
- 2017-03-24 EC ECIEPI201718120A patent/ECSP17018120A/en unknown
- 2017-03-27 IL IL251420A patent/IL251420A0/en unknown
- 2017-03-31 SV SV2017005419A patent/SV2017005419A/en unknown
- 2017-04-04 CL CL2017000817A patent/CL2017000817A1/en unknown
- 2017-04-04 PH PH12017500621A patent/PH12017500621A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017530173A (en) | 2017-10-12 |
| IL251420A0 (en) | 2017-05-29 |
| CN106715438A (en) | 2017-05-24 |
| RU2017111888A (en) | 2018-11-12 |
| PE20180024A1 (en) | 2018-01-09 |
| US20170298072A1 (en) | 2017-10-19 |
| JP6596489B2 (en) | 2019-10-23 |
| SV2017005419A (en) | 2017-06-07 |
| AR102227A1 (en) | 2017-02-15 |
| EA201790575A1 (en) | 2017-07-31 |
| AU2015329898A1 (en) | 2017-03-30 |
| MX2017004510A (en) | 2017-06-28 |
| PH12017500621A1 (en) | 2017-09-25 |
| CN106715438B (en) | 2019-04-12 |
| TW201629064A (en) | 2016-08-16 |
| ES2735733T3 (en) | 2019-12-20 |
| ECSP17018120A (en) | 2017-08-31 |
| TN2017000099A1 (en) | 2018-07-04 |
| US10150771B2 (en) | 2018-12-11 |
| DOP2017000080A (en) | 2017-05-15 |
| EP3204387A1 (en) | 2017-08-16 |
| KR20170066417A (en) | 2017-06-14 |
| WO2016055618A1 (en) | 2016-04-14 |
| CL2017000817A1 (en) | 2017-11-03 |
| CA2961986A1 (en) | 2016-04-14 |
| CO2017002708A2 (en) | 2017-06-30 |
| BR112017006940A2 (en) | 2018-01-09 |
| EP3204387B1 (en) | 2019-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287113A (en) | Smyd inhibitors | |
| IL251420A0 (en) | Triazolopyrazinones as pde1 inhibitors | |
| HK1249097A1 (en) | Imidazotriazinones as pde1 inhibitors | |
| IL246785A0 (en) | Benzimidazol-2-amines as midh1 inhibitors | |
| HK1226398A1 (en) | Benzimidazol-2-amines as midh1 inhibitors | |
| IL248895A0 (en) | Phosphatidylinositol -kinase inhibitors | |
| HK1252098B (en) | Imidazopyrazinones as pde1 inhibitors | |
| GB201501004D0 (en) | Inhibitors | |
| IL252866A0 (en) | Imidazopyridazine derivatives as pi3kb inhibitors | |
| IL248078B (en) | Halogenated quinazolin-thf-amines as pde1 inhibitors | |
| HK1232214A1 (en) | Hexahydrofuropyrroles as pde1 inhibitors pde1 | |
| GB201401005D0 (en) | Inhibitor | |
| GB201520949D0 (en) | Inhibitors | |
| GB201418154D0 (en) | Inhibitors |